Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.44 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222008 | 0.83 | RAB9A (0.43) | MAPTPPARARAB9A | |
| SCHEMBL18281760 | 0.82 | TDP1 (0.41) | ALDH1A1MAPTRAB9AMAOB | |
| SCHEMBL18282027 | 0.82 | RXRA (0.41) | RAB9A | |
| SCHEMBL227612 | 0.81 | AR (0.47) | AR | |
| SCHEMBL226788 | 0.80 | ALDH1A1 (0.41) | ALDH1A1MAPTPPARA | |
| SCHEMBL227191 | 0.78 | ALDH1A1 (0.45) | ALDH1A1MAPTMMP2MMP3AR | |
| SCHEMBL13520469 | 0.76 | AR (0.54) | ALDH1A1MAPTMMP2MMP3AR | |
| SCHEMBL14263051 | 0.76 | AR (0.54) | ALDH1A1MAPTMMP2MMP3AR | |
| SCHEMBL12378041 | 0.76 | AR (0.54) | ALDH1A1MAPTMMP2MMP3AR | |
| SCHEMBL1997781 | 0.74 | MAPT (0.48) | ALDH1A1MAPTMMP2MMP3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | ALDH1A1 1111/4885MAPT 3989/4885MMP2 3730/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ALDH1A1 1214/4885MAPT 3856/4885MMP2 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.